Skip to main content

Main menu

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Practice

Management of dyspnea at the end of life

Michael P. Slawnych
CMAJ May 19, 2020 192 (20) E550; DOI: https://doi.org/10.1503/cmaj.200488
Michael P. Slawnych
Division of Palliative Care and Libin Cardiovascular Institute, University of Calgary, Calgary, Alta.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF
Loading
Submit a Response to This Article
Compose Response

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
References
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'. Minimum 7 characters.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'. Minimum 12 characters.
Your organization, institution's or residential address.
Statement of Competing Interests

Vertical Tabs

Jump to comment:

  • RE: Role of benzodiazepines in dyspnea
    Chris C Frank [MD, FCFP (COE,PC)] and Danielle Kain [MA,MD,CCFP (PC)]
    Posted on: 27 July 2020
  • Posted on: (27 July 2020)
    RE: Role of benzodiazepines in dyspnea
    • Chris C Frank [MD, FCFP (COE,PC)], Care of the Elderly and Palliative Medicine, Queen's University
    • Other Contributors:
      • Danielle Kain, Palliative Medicine

    We thank Dr Slawnych for his excellent “Practice” article on dyspnea and agree, “No one should die suffering from breathlessness”. We wish to provide observations on the role of benzodiazepines, antipsychotics and other psychotropics for dyspnea, from our perspective as palliative care providers. Like Dr. Slawnych, we acknowledge the dearth of evidence supporting clinical practice.

    Dr Slawnych mentions the use of benzodiazepines as second line agents if symptoms persist despite opioids. We appreciate that there is mention of referral to palliative medicine physicians in these circumstances. However, given limited access to this specialty, we are concerned that this recommendation may lead to increased use of benzodiazepines. A 2016 Cochrane review notes that benzodiazepines have limited efficacy for dyspnea, although they are potentially helpful for anxiety caused by the sensation of dyspnea1. Similarly, the Cancer Care Ontario guidelines suggest use of benzodiazepines for anxiety in patients who have higher PPS and do not recommend them for dyspnea itself2.

    The article comments on the role of antipsychotics such as methotrimeprazine for management of agitation related to dyspnea but there is some evidence of benefits for specific antipsychotics for dyspnea itself. As with benzodiazepines there is limited evidence but our experience is they have the potential to alleviate dyspnea, not just agitation, and may be especially relevant later in the course of illn...

    Show More

    We thank Dr Slawnych for his excellent “Practice” article on dyspnea and agree, “No one should die suffering from breathlessness”. We wish to provide observations on the role of benzodiazepines, antipsychotics and other psychotropics for dyspnea, from our perspective as palliative care providers. Like Dr. Slawnych, we acknowledge the dearth of evidence supporting clinical practice.

    Dr Slawnych mentions the use of benzodiazepines as second line agents if symptoms persist despite opioids. We appreciate that there is mention of referral to palliative medicine physicians in these circumstances. However, given limited access to this specialty, we are concerned that this recommendation may lead to increased use of benzodiazepines. A 2016 Cochrane review notes that benzodiazepines have limited efficacy for dyspnea, although they are potentially helpful for anxiety caused by the sensation of dyspnea1. Similarly, the Cancer Care Ontario guidelines suggest use of benzodiazepines for anxiety in patients who have higher PPS and do not recommend them for dyspnea itself2.

    The article comments on the role of antipsychotics such as methotrimeprazine for management of agitation related to dyspnea but there is some evidence of benefits for specific antipsychotics for dyspnea itself. As with benzodiazepines there is limited evidence but our experience is they have the potential to alleviate dyspnea, not just agitation, and may be especially relevant later in the course of illness. Additionally, there is emerging evidence that serotonin may play a role in the experience of dyspnea; studies investigating the use of medications that increase serotonin are underway3. Opiates, benzodiazepines, and antipsychotics all have potential for side effects such as confusion, falls, and drowsiness and the choice of second line agents should depend on the nature of symptoms, frailty of the patient, and where they are at in the course of their illness. Finally, there is reasonable-quality evidence for use of non-pharmacological interventions such as a fan on the face, cooler temperatures, and body positioning – and these should certainly be optimized before adding pharmacological agents.

    We recognize that the format of the CMAJ paper limits nuance but did want to ensure that it does not lead to excess use of benzodiazepines by physicians with less experience in palliative care or limited opportunities to access clinical support.

    Show Less
    Competing Interests: None declared.

    References

    • Michael P. Slawnych. Management of dyspnea at the end of life. CMAJ 2020;192:E550-E550.
    • 1. Simon ST, Higginson IJ, Booth S, Harding R, Weingärtner V, Bausewein C. Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults. Cochrane Database Syst Rev. 2016;10(10):CD007354. Published 2016 Oct 20
    • 2. Cancer Care Ontario Dyspnea Algorithm https://www.cancercareontario.ca/en/symptom-management/3126
    • 3. Watts GJ, Clark K, Agar M et al Study protocol: a phase III randomised, double-blind, parallel arm, stratified, block randomised, placebo-controlled trial investigating the clinic effect and cost-effectiveness of sertraline for the palliative relief of
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 192 (20)
CMAJ
Vol. 192, Issue 20
19 May 2020
  • Table of Contents
  • Index by author

Article extras

  • Podcast

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Management of dyspnea at the end of life
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Management of dyspnea at the end of life
Michael P. Slawnych
CMAJ May 2020, 192 (20) E550; DOI: 10.1503/cmaj.200488

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Management of dyspnea at the end of life
Michael P. Slawnych
CMAJ May 2020, 192 (20) E550; DOI: 10.1503/cmaj.200488
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • No one should die suffering from breathlessness
    • Opioids are the mainstay for managing dyspnea at the end of life
    • If dyspnea persists, a benzodiazepine may be added
    • Patients often develop bothersome secretions owing to swallowing difficulties
    • Patients’ dyspnea-related agitation can distress their loved ones
    • Footnotes
    • References
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF

Related Articles

  • Prise en charge de la dyspnée en fin de vie
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • “Superscan” in diffusion-weighted imaging with background body suppression magnetic resonance imaging
  • Using intranasal corticosteroids
  • Langerhans cell histiocytosis in a 5-month-old baby
Show more Practice

Similar Articles

Collections

  • Sections
    • Five Things to Know About
  • Topics
    • Infectious diseases: COVID-19
    • Palliative medicine
    • Family medicine, general practice, primary care
    • Drugs: pain (including opioids)

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions

Copyright 2021, Joule Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

Powered by HighWire